https://charts.traderzeitung.de/phases/US14888U1016
string(1426) "{"isin":"US14888U1016","name":"Catalyst Pharmaceuticals Inc","stock_id_xnas":7873473,"stock_id_xnys":null,"generated_at":"2026-07-08 14:30:00","days":[{"date":"2026-07-02","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":31.47,"close_at":"2026-07-02 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"24:00","close":31.46,"close_at":"2026-07-02 22:00:00","complete":true,"perf_pct":-0.0318}]},{"date":"2026-07-06","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":31.47,"close_at":"2026-07-06 16:07:00","complete":true,"perf_pct":0.0318},{"phase":3,"label":"post","from":"22:00","to":"24:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-07-07","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":31.475,"close_at":"2026-07-07 21:59:00","complete":true,"perf_pct":0.0159},{"phase":3,"label":"post","from":"22:00","to":"24:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"
Catalyst Pharmaceuticals Aktie News & Nachrichten

Catalyst Pharmaceuticals Aktie News & Nachrichten

[WKN: A0LCUL | Symbol: CPRX]
Realtimekurs
   
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel
Catalyst Pharmaceuticals Chart

Catalyst Pharmaceuticals: Wachstumsstarker Spezialist für seltene Krankheiten

  Erfolgreich mit Orphan Drugs:  Catalyst punktet mit margenstarken Nischenprodukten wie FIRDAPSE...

Catalyst Pharmaceuticals: Ein aufstrebender Akteur im Bereich seltener Krankheiten

Gezielte Lizenzierung:  Catalyst erwirbt Medikamente für seltene Krankheiten kurz vor deren Markteinführung. ...

  • 1
MT Newswires 24.06.2026 12:30 Uhr

Fusion von Catalyst und Angelini Pharma erhält vorzeitige Beendigung der Wartezeit gemäß HSR Act

06:29 AM EDT, 06/24/2026 (MT Newswires) -- Das Fusionsabkommen von Catalyst Pharmaceuticals (CPRX) mit Angelini Pharma und Angelini Cielo erhielt die